FOLH1 and prostate carcinoma: The prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein overexpressed on nearly all prostate cancer (PCa) cells, has gained prominence as a molecular target for imaging and therapy of PCa [1,2,3].